stoxline Quote Chart Rank Option Currency Glossary
  
Hillstream BioPharma, Inc. (HILS)
0.237  0.013 (5.66%)    09-22 15:59
Open: 0.225
High: 0.2448
Volume: 313,195
  
Pre. Close: 0.2243
Low: 0.2201
Market Cap: 4(M)
Technical analysis
2023-12-01 4:20:27 PM
Short term     
Mid term     
Targets 6-month :  0.33 1-year :  0.44
Resists First :  0.28 Second :  0.37
Pivot price 0.18
Supports First :  0.14 Second :  0.11
MAs MA(5) :  0.18 MA(20) :  0.18
MA(100) :  0.25 MA(250) :  0.51
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  39.2 D(3) :  32.7
RSI RSI(14): 54.1
52-week High :  2.65 Low :  0.14
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ HILS ] has closed below upper band by 23.4%. Bollinger Bands are 31.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.21 - 0.21 0.21 - 0.22
Low: 0.17 - 0.17 0.17 - 0.17
Close: 0.21 - 0.21 0.21 - 0.21
Company Description

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Headline News

Fri, 22 Mar 2024
Hillstream BioPharma (NASDAQ:HILS) Stock Price Down 1.2% - Defense World

Fri, 22 Sep 2023
Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change ... - Yahoo Finance

Tue, 02 May 2023
Hillstream BioPharma Announces Closing of Public Offering of Common Stock - Yahoo Finance

Thu, 27 Apr 2023
Hillstream BioPharma Announces Proposed Public Offering - GlobeNewswire

Thu, 27 Apr 2023
Hillstream BioPharma Announces Pricing of Public Offering - GlobeNewswire

Wed, 12 Apr 2023
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To ... - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Neutral
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 18 (M)
Shares Float 11 (M)
Held by Insiders 38.9 (%)
Held by Institutions 0.8 (%)
Shares Short 53 (K)
Shares Short P.Month 133 (K)
Stock Financials
EPS -0.7
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.18
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) -78 %
Return on Equity (ttm) -147.4 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow -7 (M)
Levered Free Cash Flow -4 (M)
Stock Valuations
PE Ratio -0.3
PEG Ratio 0
Price to Book value 1.16
Price to Sales 0
Price to Cash Flow -0.5
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android